Join us for a LIVE case followed by a recorded case highlighting advanced treatments for severe secondary mitral regurgitation:

• A 75-year-old man with permanent AF, a history of CABG, and symptomatic severe secondary MR (atrial and ischemic causes) with low LV function (45%) underwent mitral repair with...

A 53-year-old male with a history of advanced malignancy (lung adenoma) and mid LAD PCI last year, along with multiple risk factors (hypertension, dyslipidemia, diabetes, and smoking), presented with angina and a positive stress test and CT. The angiography and CT showed significant left main stenosis...

An 82-year-old male with a history of STEMI in 2013, stroke in 2018, cancer, and permanent AF, presented with acute heart failure with predominant right-side failure. Severe tricuspid regurgitation was identified.
The operators implanted an Evoque valve percutaneously under TEE guidance and general anaesthesia via the venous...

A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.

A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...

An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

Consult the references associated to the clinical research and case reports in coronary guidewire loss complications.

Hypertension is the number one cause of years of life lost, and, perhaps more importantly, years of healthy living lost. It causes at least half of all heart attacks and strokes and is the major driver of heart failure.

Lucas Lauder and Felix Mahfoud provide a summary of the ESC Guidelines on elevated blood pressure and hypertension presented by John William McEvoy and Rhian Touyz at ESC Congress 2024 in London.

Paris, France, 22 May 2019. Identification and management of patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) is of major importance, but a lack of standardisation in defining this population limits trial design, data interpretation, and clinical decision-making.

The 6-month follow-up of the TRISCEND study was presented during the TCT Congress 2021 by principal investigator Susheel Kodali. Alessandro Sticchi & Jonathan Curio offer a review of this trial.

EuroPCR, the annual world-leading Course in interventional cardiovascular medicine, has been taking place for over 30 years. It is tailored for all those dedicated to the sharing of knowledge and skills, and improvement of patient care worldwide: interventional cardiologists, cardiac surgeons, imaging specialists, radiologists, nurses, allied...

Alex Sticchi provides his take on the 5-year outcomes from PARTNER 3 Low Risk which were presented by Martin B. Leon at TCT Congress 2023.

Ali Nazmi Calik provides his take on UNIVERSAL randomized clinical trial, which questioned whether routine ultrasonography guidance for CFA access for cardiac procedures reduces bleeding or vascular complications. This trial was presented by Sanjit S. Jolly during TCT 2022.

Ali Nazmi Calik provides his take on the FLAVOUR II trial presented by Jian-An Wang at ACC.25 in Chicago.

In collaboration with EuroIntervention Journal

The authors decided to create a survey tailored for ICTs in order to assess the changes in their training. Capturing the essence of the responses may help to identify the most appropriate strategies to provide the highest standards and skills achievements in COVID-19...

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)

Claudio Laudani and Daniele Giacoppo report the main results of the ILUMIEN IV trial presented by Ziad Ali, from the St. Francis Hospital, Roslyn, and Clinical Trials Center, Cardiovascular Research Foundation, New York, in a Hot Line session at the European Society of Cardiology congress 2023...